Trial Outcomes & Findings for Informational Nudge to Improve Heart Failure Prescribing (NCT NCT05986695)

NCT ID: NCT05986695

Last Updated: 2026-05-01

Results Overview

The primary effectiveness outcome is the amount of SGLT2 or MRA prescriptions in eligible HF patients in the three intervention groups compared with the control group within 30 days of appointment. Thirty days is a common time interval for HF outcomes assessment and allows for chart documentation, care coordination, laboratory testing, and medication prescribing that may occur days after a patient encounter. The investigators will record all SGLT2 or MRA prescriptions, including those from non-targeted clinicians, given that nudge interventions, especially the informational alert, may impact other clinicians directly (e.g., view alert in EHR) or indirectly (e.g., referral from targeted clinician). Data represent a cumulative number of prescriptions filled.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

81 participants

Primary outcome timeframe

30 days

Results posted on

2026-05-01

Participant Flow

All employed providers within Cardiology and Primary Care units were enrolled into this study per agreement with management.

The leadership of both units agreed that all providers would participate. The 81 participants (providers) were randomly assigned to one of four study arms (control, Alert \[EHR note\], Pier Comparison Report \[Email notification\], or Both \[EHR and Email\]. The providers were numbered and blindly randomize by department, education, and employment site.

Participant milestones

Participant milestones
Measure
Control
Participants within this arm will not receive any intervention.
Alert
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note.
Peer Comparison Report
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
Alert & Peer Comparison Report
Participants within this arm would receive the EHR note 2 days prior to an eligible patient and an Email alert every 15 days regarding their ranking concerning the guideline directed medication.
Overall Study
STARTED
19
19
21
22
Overall Study
COMPLETED
19
19
21
22
Overall Study
NOT COMPLETED
0
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Informational Nudge to Improve Heart Failure Prescribing

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 30 days

Population: The primary effectiveness outcome is the amount of SGLT2 or MRA prescriptions in eligible HF patients in the three intervention groups compared with the control group within 30 days of appointment. The investigators' focus was on increasing the prescription rate. Participants analyzed reflect count of patients.

The primary effectiveness outcome is the amount of SGLT2 or MRA prescriptions in eligible HF patients in the three intervention groups compared with the control group within 30 days of appointment. Thirty days is a common time interval for HF outcomes assessment and allows for chart documentation, care coordination, laboratory testing, and medication prescribing that may occur days after a patient encounter. The investigators will record all SGLT2 or MRA prescriptions, including those from non-targeted clinicians, given that nudge interventions, especially the informational alert, may impact other clinicians directly (e.g., view alert in EHR) or indirectly (e.g., referral from targeted clinician). Data represent a cumulative number of prescriptions filled.

Outcome measures

Outcome measures
Measure
Control
n=10 Participants
Participants within this arm will not receive any intervention.
Alert
n=26 Participants
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
Peer Comparison Report
n=21 Participants
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
Both Alert and Peer Comparison Report
n=18 Participants
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Effectiveness (MRA Prescriptions)
0 Count of MRA prescriptions Filled
2 Count of MRA prescriptions Filled
2 Count of MRA prescriptions Filled
2 Count of MRA prescriptions Filled

PRIMARY outcome

Timeframe: 30 days

Population: The primary effectiveness outcome is the amount of SGLT2 or MRA prescriptions in eligible HF patients in the three intervention groups compared with the control group within 30 days of appointment. The investigators' focus was on increasing the prescription rate. Participants analyzed reflect count of patients.

The primary effectiveness outcome is the amount of SGLT2 or MRA prescriptions in eligible HF patients in the three intervention groups compared with the control group within 30 days of appointment. Thirty days is a common time interval for HF outcomes assessment and allows for chart documentation, care coordination, laboratory testing, and medication prescribing that may occur days after a patient encounter. The investigators will record all SGLT2 or MRA prescriptions, including those from non-targeted clinicians, given that nudge interventions, especially the informational alert, may impact other clinicians directly (e.g., view alert in EHR) or indirectly (e.g., referral from targeted clinician). Data represent a cumulative number of prescriptions filled.

Outcome measures

Outcome measures
Measure
Control
n=55 Participants
Participants within this arm will not receive any intervention.
Alert
n=122 Participants
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
Peer Comparison Report
n=54 Participants
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
Both Alert and Peer Comparison Report
n=98 Participants
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Effectiveness (SGLT2 Prescriptions)
2 Count of SGLT2 Prescriptions Filled
24 Count of SGLT2 Prescriptions Filled
1 Count of SGLT2 Prescriptions Filled
16 Count of SGLT2 Prescriptions Filled

SECONDARY outcome

Timeframe: 6 months

Population: This is the number of clinicians within Primary Care and Cardiology who were participants.

Reach will be measured at the clinician level as the number of unique clinicians who received an informational alert or peer comparison report. The control group did not receive any alert.

Outcome measures

Outcome measures
Measure
Control
n=19 Participants
Participants within this arm will not receive any intervention.
Alert
n=19 Participants
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
Peer Comparison Report
n=21 Participants
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
Both Alert and Peer Comparison Report
n=22 Participants
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Reach-Clinician
0 Participants
19 Participants
21 Participants
22 Participants

SECONDARY outcome

Timeframe: 30 days

Population: The deprescribed medicine rate was determined by patient and not associated directly with the participants (clinicians) nor Arms/Groups, being that a patient may be seen by multiple providers.

The investigators will measure safety as the number of patients who were deemed by the participant (clinician) to discontinued prescribed medicine due to suspected adverse effects within 30 days of the nudge interventions.

Outcome measures

Outcome measures
Measure
Control
n=234 Participants
Participants within this arm will not receive any intervention.
Alert
n=151 Participants
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
Peer Comparison Report
n=169 Participants
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
Both Alert and Peer Comparison Report
n=234 Participants
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
Peer Comparison Report (Group 3) MRA Deprescribed
n=151 Participants
Number of patients that were removed from the guideline directed medication as determined by participants
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
n=169 Participants
Number of patients that were removed from the guideline directed medication as determined by participants
Incidence of Treatment Emergent Adverse Events
3 Deprescribed patients
0 Deprescribed patients
2 Deprescribed patients
1 Deprescribed patients
0 Deprescribed patients
0 Deprescribed patients

SECONDARY outcome

Timeframe: 6 months

Population: Surveys were anonymous and no identifying information was collected, therefore, investigators are unable to determine which Arm/Group participants with survey responses were assigned. Rows represent responses from the surveys and do not correspond to a specific Arm/Group. The survey was voluntary and only 14 of the 81 clinicians participated.

Implementation will be assessed by clinician-directed survey of Acceptability of intervention Measure. The REDCap survey was on the Likert Scale: minimum 1 and maximum 5. With 5 being the highest. Acceptability was determine by the number of participants who were neutral or positive with their responses according the the Likert Scale. The anonymous surveys were sent to all in the three groups and did not collect any identifying information.

Outcome measures

Outcome measures
Measure
Control
n=14 Participants
Participants within this arm will not receive any intervention.
Alert
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
Peer Comparison Report
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
Both Alert and Peer Comparison Report
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Implementation-Acceptability
Acceptability of the Intervention Measure for the Alert
4 Participants
Implementation-Acceptability
Acceptability of the Intervention Measure for the Peer Comparison Report
2 Participants

SECONDARY outcome

Timeframe: 6 months

Population: The number of patients were not broken down by each participant nor Arm/Group.

At the patient level, Reach will be measured as the number of unique patients for whom the participants received informational alerts

Outcome measures

Outcome measures
Measure
Control
n=604 Participants
Participants within this arm will not receive any intervention.
Alert
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
Peer Comparison Report
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
Both Alert and Peer Comparison Report
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Reach-Patient
604 Total unique patients

SECONDARY outcome

Timeframe: 6 months

The investigators will measure the proportion of alerts relative to the total number of eligible patients with HF; this denominator will allow for comparisons of representativeness of the alert strategy.

Outcome measures

Outcome measures
Measure
Control
n=19 Participants
Participants within this arm will not receive any intervention.
Alert
n=19 Participants
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
Peer Comparison Report
n=21 Participants
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
Both Alert and Peer Comparison Report
n=22 Participants
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Reach-Comparison of Strategies
0 alerts sent
211 alerts sent
202 alerts sent
191 alerts sent

SECONDARY outcome

Timeframe: 6 months

Population: Surveys were anonymous and no identifying information was collected, therefore, investigators are unable to determine which Arm/Group participants with survey responses were assigned. Rows represent responses from the surveys and do not correspond to a specific Arm/Group. The survey was voluntary and only 10 of the 81 clinicians participated.

Appropriateness will be assessed by clinician direct survey of Intervention Appropriateness Measure. Likert scale: minimum 1 and maximum 5. With 5 being the highest. The number of respondents who were neutral and positive were counted. The anonymous surveys were sent to all in the three groups and did not collect any identifying information.

Outcome measures

Outcome measures
Measure
Control
n=10 Participants
Participants within this arm will not receive any intervention.
Alert
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
Peer Comparison Report
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
Both Alert and Peer Comparison Report
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Implementation-Appropriateness
Intervention Appropriateness Measure for the Alert
5 Participants
Implementation-Appropriateness
Intervention Appropriateness Measure for the Peer Comparison Report
0 Participants

SECONDARY outcome

Timeframe: 6 months

Population: Surveys were anonymous and no identifying information was collected, therefore, investigators are unable to determine which Arm/Group participants with survey responses were assigned. Rows represent responses from the surveys and do not correspond to a specific Arm/Group. The survey was voluntary and only 10 of the 81 clinicians participated.

Feasibility will be assessed by clinician direct survey of Feasibility of Intervention Measure. Likert scale: minimum 1 and maximum 5. With 5 being the highest. The survey participants responded used the Likert scale to determine if the intervention would be feasible. All responses neutral or positive were counted. The anonymous surveys were sent to all in the three groups and did not collect any identifying information.

Outcome measures

Outcome measures
Measure
Control
n=10 Participants
Participants within this arm will not receive any intervention.
Alert
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
Peer Comparison Report
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
Both Alert and Peer Comparison Report
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
Implementation-Feasibility
Feasibility of the Intervention Measure for the Alert
4 Participants
Implementation-Feasibility
Feasibility of the Intervention Measure for the Peer Comparison Report
1 Participants

Adverse Events

Peer Comparison Report

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Alert & Peer Comparison Report

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Alert

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Sandesh Dev

Tucson VA Medical Center

Phone: (602) 888-1257

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place